Insider · CIK 0001404955
Seth Loring Harrison
director
Files at STOK (Stoke Therapeutics, Inc.), AKRO (Akero Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | DDisposition to issuer Common Stock | -136,301 | - | - | 0 | Dec 9, 2025 |
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | DDisposition to issuer Common Stockindirect: See Footnote | -148,063 | - | - | 0 | Dec 9, 2025 |
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | DDisposition to issuer Common Stock | -9,398 | - | - | 0 | Dec 9, 2025 |
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -26,000 | - | - | 0 | Dec 9, 2025 |
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,000 | - | - | 0 | Dec 9, 2025 |
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -15,000 | - | - | 0 | Dec 9, 2025 |
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,000 | - | - | 0 | Dec 9, 2025 |
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,000 | - | - | 0 | Dec 9, 2025 |
| Dec 9, 2025 | AKRO Akero Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -26,000 | - | - | 0 | Dec 9, 2025 |
| Jun 3, 2025 | AKRO Akero Therapeutics, Inc. | AGrant or award Common Stock | +9,398 | $0.00 | $0 | 145,699 | Jun 5, 2025 |
| Jun 3, 2025 | STOK Stoke Therapeutics, Inc. | AGrant or award Director Stock Option (Right to Buy)derivative | +29,747 | $0.00 | $0 | 29,747 | Jun 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.